Browse resources

Disease: Meningococcus

Total results with these characteristics: 193

Page 2 of 8  
‹ prev.
1
2
3
4
5
next ›

Costs and Impact of Meningitis Epidemics for the Public Health System in Burkina Faso

Epidemic meningococcal meningitis remains a serious health threat in the African meningitis belt. New meningococcal conjugate vaccines are relatively costly and their efficiency will depend on cost savings realized from no longer having to respond …

Author: Colombini A, Badolo O, Gessner BD, Jaillard P, Seini E, Da Silva A

Published: 2011

Costs for Households and Community Perception of Meningitis Epidemics in Burkina Faso

This article, published in Clinical Infectious Diseases, discusses an anthropologic and economic study in Burkina Faso to understand perceptions and behavior relative to meningitis and to determine the cost of illness from bacterial …

Author: Colombini A, Bationo F, Zongo S, et al.

Published: 2009

Costs of Meningitis Sequelae in Children in Dakar, Senegal

In economic evaluations of vaccines protecting against meningitis, treatment and productivity costs due to meningitis sequelae are rarely included in studies from low-income countries, mainly due to lack of data. This study, published in The …

Author: Griffiths UK, Dieye Y, Fleming J, Hajjeh R, Edmond K

Published: 2012

Critical Episodes in the Understanding and Control of Epidemic Meningococcal Meningitis

Epidemic meningococcal meningitis continues to be an important worldwide cause of morbidity and mortality, especially in developing countries. Throughout its history, a number of "critical episodes" have occurred that have enhanced understanding of …

Author: Artenstein AW, LaForce FM

Published: 2012

Definition and Characterization of Localised Meningitis Epidemics in Burkina Faso: A Longitudinal Retrospective Study

The epidemiology of meningococcal meningitis in the African meningitis belt is characterized by seasonality, localized epidemics, and epidemic waves. To facilitate research and surveillance, the authors of this article, published in BMC Infectious …

Author: Tall H, Hugonnet S, Donnen P, et al.

Published: 2012

Delivering MenAfriVac Using the Controlled Temperature Chain Approach

In November 2012, the first immunization campaign to use a controlled temperature chain (CTC) took place in northern Benin. This photo set by project Optimize contains images taken during the campaign, where more than 155,000 people were vaccinated …

Author: PATH, World Health Organization

Published: 2013

Detecting Meningococcal Meningitis Epidemics in Highly-Endemic African Countries

This article, published in the World Health Organization's (WHO's) Weekly Epidemiological Record, provides the WHO recommendation for detecting and responding to meningococcal meningitis epidemics in highly-endemic countries in Africa. In each …

Author: World Health Organization

Published: 2000

Development of a Group A Meningococcal Conjugate Vaccine, MenAfriVac™

Group A meningococcal disease has been an important public health problem in sub-Saharan Africa for over a century. From 2003 to 2009 a monovalent group A conjugate vaccine, MenAfriVac™, was developed through an innovative public/private …

Author: Frasch C, Preziosi M-P, LaForce FM

Published: 2012

Development of Vaccines Against Meningococcal Disease

This article, published in the Lancet, reviews the currently available vaccines against meningococcal disease, as well as research and development efforts toward the development of additional vaccines against the disease. ABSTRACT …

Author: Jódar L, Feavers IM, Salisbury D, Granoff DM

Published: 2002

Disease Outbreak News

This web page provides frequently updated information about current disease outbreaks, as well as disease-specific archives of past alerts and links to related resources.

Author: World Health Organization

Dynamic Models of Meningococcal Carriage, Disease, and the Impact of Serogroup C Conjugate Vaccination

The authors of this article, published in The American Journal of Epidemiology, use data on immunization with serogroup C meningococcal conjugate vaccines in England and Wales to develop and apply a mathematical model that investigates the …

Author: Trotter CL, Gay NJ, Edmunds WJ

Published: 2005

Effect of a Serogroup A Meningococcal Conjugate Vaccine (PsA—TT) on Serogroup A Meningococcal Meningitis and Carriage in Chad: A Community Study

A serogroup A meningococcal polysaccharide—tetanus toxoid conjugate vaccine (PsA—TT, MenAfriVac) was licensed in India in 2009, and prequalified by the World Health Organization in 2010, on the basis of its safety and immunogenicity. This …

Author: Daugla DM, Gami JP, Gamougam K, et al.

Published: 2013

Effect of Vaccines on Bacterial Meningitis Worldwide

This article, published in The Lancet, focuses on the three most common causes of acute bacterial meningitis: Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis. The authors compare patterns of meningitis attributable to …

Author: McIntyre PB, O'Brien KL, Greenwood B, van de Beek D

Published: 2012

Effectively Introducing a New Meningococcal A Conjugate Vaccine in Africa: The Burkina Faso Experience

In 2010, Burkina Faso conducted a country-wide campaign to introduce a new Group A meningococcal conjugate vaccine, MenAfriVac™. Leading up to this effort, the following challenges were successfully managed: (1) conducting a large safety study …

Author: Djingarey MH, Barry R, Bonkoungou M, et al.

Published: 2012

Effectiveness of Meningococcal Serogroup C Vaccine Programmes

Since the introduction of monovalent meningococcal serogroup C (MenC) glycoconjugate (MCC) vaccines and the implementation of national vaccination programs, the incidence of MenC disease has declined markedly as a result of effective short-term …

Author: Borrow R, Abad R, Trotter C, van der Kils FRM, Vazquez JA

Published: 2013

Eliminating Epidemic Group A Meningococcal Meningitis in Africa Through a New Vaccine

This article, published in Health Affairs, discusses a new affordable vaccine against Group A meningococcus, the most common cause of large and often fatal African epidemics of meningitis, that was introduced in Burkina Faso, Mali, and Niger in …

Author: LaForce FM, Okwo-Bele J-M

Published: 2011

Emergence of Serogroup X Meningococcal Disease in Africa: Need for a Vaccine

This article, published in Vaccine, describes how and why serogroup X meningococcal disease has emerged in Africa in recent years. It asserts that while no licensed vaccine is available against serogroup X meningococci, following the introduction of …

Author: Xie O, Pollard AJ, Mueller JE, Norheim G

Published: 2013

Emergency or Routine Vaccination Against Meningococcal Disease in Africa?

This comment, published in The Lancet, is based on a review of the study "Emergency Vaccination Against Epidemic Meningitis in Ghana: Implications for the Control of Meningococcal Disease in West Africa." The author concludes that …

Author: Peltola H

Published: 2000

Emergency Vaccination Against Epidemic Meningitis in Ghana: Implications for the Control of Meningococcal Disease in West Africa

This article, published in The Lancet, assessed the potential effects of different vaccination strategies against meningococcal disease using data from the 1997 meningococcal outbreak in northern Ghana. Using a simple mathematical model, …

Author: Woods CW, Armstrong G, Sackey SO, et al.

Published: 2000

Environmental Risk and Meningitis Epidemics in Africa

This study, published in Emerging Infectious Diseases, provides evidence that the relationship between the environment and the location of meningitis epidemics is quantifiable. The study proposes a model based on environmental …

Author: Molesworth AM, Cuevas LF, Connor SJ, Morse AP, Thomson MC

Published: 2003

Epidemic Meningitis Due to Group A Neisseria Meningitidis in the African Meningitis Belt: A Persistent Problem With an Imminent Solution

This article, published in the journal Vaccine, emphasizes Group A Neisseria meningitidis as a health problem in Africa and disccuses the potential for a proactive control strategy for epidemic meningitis with the use of …

Author: LaForce FM, Ravenscroft N, Djingarey M, et al

Published: 2009

Epidemiological Profile of Meningococcal Disease in the United States

Published in Clinical Infectious Diseases, this article discusses the current epidemiological profile of meningococcal disease and the vaccines that are currently available in the United States. The article also outlines what would be required for a …

Author: Harrison LH

Published: 2010

Epidemiology of Bacterial Meningitis in Niamey, Niger, 1981-96

This study, published in the Bulletin of the World Health Organization, used retrospective surveillance to identify cases of laboratory-diagnosed bacterial meningitis in Niamey, Niger, from 1981 to 1996. The study analyzed the cases …

Author: Campagne G, Schuchat A, Djibo S, et al.

Published: 1999

The Epidemiology of Meningococcal Disease and the Impact of Vaccines

Neisseria meningitidis causes meningococcal disease, a severe bacterial infection of the bloodstream or meninges, worldwide. The disease is most common among young children, but the existing polysaccharide vaccines have been sparsely used because …

Author: Khatami A, Pollard AJ

Published: 2010

Epidemiology of Meningococcal Disease in Latin America: Current Situation and Opportunities for Prevention

This article, published in Neurological Research, discusses the changes in the epidemiology of meningococcal disease in Latin America and comments on the development and potential impact of new vaccines for the prevention of the disease. The authors …

Author: Sáfadi MA, Cintra OA

Published: 2010

Page 2 of 8  
‹ prev.
1
2
3
4
5
next ›